Head-to-head evidence
H002 vs JS111 AP-L1898
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: EGFR · full Non-Small Cell Lung Cancer pipeline
H002
Developed by RedCloud Bio
NCT05519293 · Phase 1/2 · status unknown
A non-randomized, open-label, sequential-cohort phase 1/2 study of H002 with an estimated 76 participants and no results posted to the registry. With no comparator arm and no posted results, this is weak evidence.
JS111 AP-L1898
Developed by Shanghai Junshi Bioscience
NCT04993391 · Phase 1/2 · status unknown
This is a single-arm, open-label, non-randomized dose-escalation study in 156 people with advanced non-small cell lung cancer, testing five ascending doses with no control group. It is designed primarily to characterize safety, with response rate as a secondary readout, and no results have been posted.
Next expected readout: July 2028 · NCT06940401 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: H002's landscape · JS111 AP-L1898's landscape